PKM and neoplasm: Interestingly, treating A549 lung carcinoma cells with OA (Fig. 2e) or EGF (Fig. 2f), which enhanced or suppressed tumour cell exosome release, respectively, we found that the level of PKM2 in A549 cells was dose-dependently decreased by OA or increased by EGF.